Novavax (NASDAQ: NVAX) started the coronavirus vaccine race as a favorite. Manufacturing issues have delayed Novavax's submission for emergency authorization in the U.S. and other countries. A news report suggested Novavax's delays may not be over.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting